Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
The University of Oxford and Selvita Collaborate to Advance Potential Therapeutics for Parkinson's Disease
The University of Oxford and Selvita, one of the largest contract research organizations in Europe, […]
Novavax Announces Participation in Oxford University Com-COV3 Booster Trial of COVID-19 Vaccines in Adolescents Aged 12 Through
Novavax is participating in a stage of the COVID-19 Vaccine Schedule Combinations (Com-COV) program initiated by the […]
Oxford Science Enterprises Strengthens Investment Teams with Two New Appointments
Oxford Science Enterprises, the Science Business Builder and preferred investment partner of the University of […]
Elysium Health™ Announces Research Partnership with the University of Oxford for the Purpose of Developing Epigenetic Measures of Brain Aging and Health
Elysium Health, Inc.™, a leading life sciences company focused on aging research, has entered into […]
University of Oxford and Oracle Cloud System Helping Researchers Identify COVID-19 Variants Faster
The fast spread of the highly infectious Delta variant underscores the need for faster identification […]
AI Breakthrough for Faster, Cheaper and Injection-free Heart Scans
New artificial intelligence (AI) technology could lead to the next generation of heart MRI scans […]
HIV Vaccine Trial HIV-CORE 0052 Starts at Oxford
The goal of the trial, known as HIV-CORE 0052, is to evaluate the safety, tolerability, […]
Novavax to Participate in Comparing Mixed COVID-19 Vaccine Combinations
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more